Modality
Cell Therapy
MOA
TYK2i
Target
MET
Pathway
Wnt
ALL
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
Jul 2018
→ Oct 2027
Phase 1Current
NCT07139539
405 pts·ALL
2025-04→TBD·Recruiting
NCT06020175
1,234 pts·ALL
2018-07→2027-10·Recruiting
1,639 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-10-071.5y awayInterim· ALL
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Recruit…
P1
Recruit…
Catalysts
Interim
2027-10-07 · 1.5y away
ALL
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07139539 | Phase 1 | ALL | Recruiting | 405 | EASI-75 |
| NCT06020175 | Phase 1 | ALL | Recruiting | 1234 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 |